MedTrace Logo

An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their Families

NCT04723693 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2024-08-19

Study results available
· View outcomes & findings →

Summary

This study aims to examine the real-life experience and impact of using emicizumab in a cohort of patients with haemophilia and inhibitors, who were prescribed emicizumab as part of the early access to medicine schema (EAMS),those who have been in clinical trials and those now receiving emicizumab as part of routine haemophilia care.

The Investigators also intend to capture the impact of emicizumab use on the lives of close family members (parents/carers/children/partners/siblings). Each participant and his family members will be deemed a study 'dyad'.

This is a prospective, observational cohort qualitative research study to be conducted among patients using emicizumab in routine clinical practice.

The study is designed to allow English-speaking patients and their families to tell their own life stories through narrative accounts. The narratives represent a true sharing of experiences and therefore offers insight into how these patients and families cope with haemophilia.

Conditions

  • Hemophilia A With Inhibitor

Interventions

OTHER

Qualitative Interview

A single one hour semi structured qualitative interview

Sponsors & Collaborators

  • Roche Chugai

    collaborator INDUSTRY

  • Haemnet

    lead OTHER

Principal Investigators

  • Simon P Fletcher, MA · Researcher

Eligibility

Min Age
8 Years
Max Age
100 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-28
Primary Completion
2021-01-31
Completion
2021-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04723693 on ClinicalTrials.gov